 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Mucositis
|
|
Kepivance® Reduces Mucositis Associated with High-dose Methotrexate (9/10/2008)
Researchers from Germany have reported that Kepivance® (palifermin, keratinocyte growth factor) reduces the incidence and severity of oral mucositis associated with high-dose methotrexate. The details of this study were reported in the September issue of the Annals of Oncology.
Chlorhexidine or Oral Cooling Decrease Chemotherapy-induced Mucositis (3/31/2008)
Researchers from Denmark have reported that chlorhexidine mouth washes or oral cooling decreases the incidence and severity of oral mucositis associated with 5 FU and leucovorin-based chemotherapy for gastrointestinal cancer. The details of this randomized study appeared in an early online publication in Cancer on February 15, 2008.
Kepivance® May Decrease Oral Mucositis Following High-Dose Chemotherapy (1/8/2007)
There were several clinical studies presented at the 2006 meeting of the American Society of Hematology in December which suggest that Kepivance (palifermin) is effective in decreasing the incidence, severity and duration of severe oral mucositis in patients with hematologic diseases receiving high-dose Alkeran® (melphalan) (200 mg/m2) or high-dose BEAM (carmustine, etoposide, cytarabine and melphalan) followed by autologous stem cell infusion.
Kepivance® Decreases Oral Mucositis in Patients with Metastatic Colorectal Cancer. (11/27/2006)
The results of a randomized multicenter trial demonstate that Kepivance (palifermin, keritinocyte growth factor) given before chemotherapy reduces the incidence of severe oral mucositis in patients receiving 5-FU/leucovorin for metastatic colorectal cancer.
Kepivance® Reduces Mucositis After Allogeneic Stem Cell Transplantation Without Impact on Acute GVHD (11/9/2006)
Researchers from the University of Minnesota and Michigan have reported that the administration of Kepivance (palifermin, keritinocyte growth factor) before and after allogeneic stem cell transplantation reduces the incidence and mean severity of mucositis in patients receiving a total body irradiation (TBI) conditioning regimen.
Daily Low Power Laser Therapy May Prevent Oral Mucositis in Stem Cell Transplant Patients (10/25/2006)
Researchers from Brazil have reported that low power laser therapy (LPLT) reduces the incidence of grade 2-4 oral mucositis by 60% following autologous or allogeneic stem cell transplantation.
L-Glutamine Effective in Prevention of Oral Mucositis After Chemoradiotherapy for Head and Neck Cancer (8/6/2006)
Researchers from Argentina have reported that the intravenous administration of L-alanyl-L-glutamine was effective in reducing the incidence and severity of oral mucositis following chemotherapy for head and neck cancer.
Oral Cryotherapy Prevents Mucositis From High-Dose Alkeran® (6/1/2006)
Researchers from the Fred Hutchinson Cancer Research Center have reported that 6 hours of exposure to oral ice chips significantly decreased the incidence of grade 3-4 oral mucositis in patients receiving 200 mg/m2 of Alkeran® (melphalan).
Kepivance™ Improves Patient-Assessed Oral Mucositis Following Autologous Stem Cell Transplantation (4/21/2006)
Patients receiving Kepivance in this study reported significant improvement in the daily functioning activities of swallowing, drinking, eating, talking and sleeping compared to the control group. This study further documents the effectiveness of Kepivance in preventing oral mucositis in the stem cell transplant setting.
Velafermin May Decrease Oral Mucositis after Autologous Transplantation (3/2/2006)
A multi-center phase II trial of the fibroblast growth factor, velafermin (CG53135), suggests that a very specific dose of this agent may decrease the severity and duration of oral mucositis associated with autologous stem cell transplantation.
The FDA Approves keratinocyte growth factor (Palifermin, Kepivance™) for Prevention of Mucositis in Patients Receiving High-Dose Chemotherapy (12/16/2004)
On December 15, 2004 the U.S. Food and Drug Administration approved the use of keratinocyte growth factor (palifermin, Kepivance™) for the treatment of patients undergoing high-dose chemoradiotherapy for hematologic malignancies. The details of the pivotal study leading to approval were published in the December 16, 2004 issue of the New England Journal of Medicine.
Palifermin Improves Quality of Life and Decreases Resource Use (12/12/2003)
Results of a phase III study reported at ASCO 2003 demonstrated that palifermin, a keratinocyte growth factor, significantly reduces the incidence and duration of severe mucositis in patients undergoing peripheral blood stem cell transplants.
1 At ASH 2003, researchers reported resource use and quality of life analysis of this study. Results indicate that palifermin significantly reduced days of hospitalization, analgesic use, and incidence of parenteral feeding. Evaluation of patient reported quality of life factors indicate that palifermin produced a clinically meaningful reduction in mouth and throat soreness and improvements in daily activities as well as physical and functional well-being.
Oral and Gastrointestinal Chemotherapy Induced Mucositis Causes Significant Clinical Problems and Increases the Costs of Treatment (9/24/2003)
Researchers from the MD Anderson Cancer Center have reported that 37% of patients with solid tumors or lymphomas develop oral and GI mucositis which leads to increased hospitalization and increased costs. Methods to decrease the incidence and severity of mucositis would have major clinical and economic benefits. These results were published in the October 2003 issue of
Cancer.(1)
|
|
Patient Home
